Bispecific antibody Tarlatamab scores in small cell lung cancer
Patients with small cell lung cancer who are treated with the bispecific T-cell engager tarlatamab in the second line likely survive longer than those treated with additional chemotherapy. This is supported by the results of the Phase III DeLLphi-304 study.
Arzte zeitung
